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Most (80%) transitional cell carcinomas (TCC) of the urinary
bladder are low stage (pTa or pT1) at initial presentation (Van der
Meiden, 1999) and may be surgically removed leaving no
detectable disease. However, 50–70% of these patients present
with a recurrence within 2 years and 20% of the recurrences
progress to detrusor muscle invasion. TCCs that invade the muscle
cannot be eradicated by endoscopic surgery alone; and 50% of
patients with this disease develop metastases and die within 5
years (Adshead et al, 1999). 
Currently only a few genetic aberrations are associated with
development and progression of TCC of the urinary bladder, e.g.
loss of chromosome 9, p53 mutations and gain of c-myc (Bartlett
et al, 1998; Tsutsumi et al, 1997; Sauter et al, 1995). Such genetic
changes may determine the path a TCC will follow (Bartlett et al,
1998; Watters et al, 2000). Several studies demonstrate genetic
differences between pTa and pT1 carcinomas (Richter et al, 1997;
Simon et al, 1998). These studies suggest that a higher level of
genetic abnormalities in pT1 carcinomas increase their likelihood
of progression. It is, however, difficult for the pathologist to accu-
rately stage pTa/pT1 carcinomas. Therefore, even if this distinc-
tion was proven, identification of the carcinoma suppressor genes
that drive TCC recurrence and/or progression would not only
increase our understanding of TCC disease development and
progression but would also enable us to predict the path an index
TCC might take. 
Loss of heterozygosity (LOH), at the region of a known tumour
suppressor gene, is considered indicative of a mutation in the
remaining copy of the gene and loss of the tumour suppressing
function of the gene product. LOH analysis of sequential carci-
nomas from TCC patients would, therefore enable tracking of
tumour suppressor gene inactivation in relation to recurrence
(Bartlett et al, 1998; Wagner et al, 1999; Watters et al, 2000). 
Deletions involving all or part of chromosome 9 are the most
frequently reported genetic event in TCC of the urinary bladder
(Bartlett et al, 1998; Knowles, 1998, 1999; Czerniak et al, 1999). We
have recently demonstrated that deletion of TSC1 on chromosome 9
predicts recurrence in a subset of TCC patients (Edwards et al, 2000).
However, in order to identify further recurrence-related genes, other
areas of deletion associated with bladder cancer should be investi-
gated. The current study has selected areas of deletion previously
associated with TCC of the bladder. LOH at 4p16.3 has been
reported in over 1/3 of bladder cancer cell lines (Bell et al, 1996) and
deletions in 8p are associated with high-grade carcinomas and distant
metastasis of urinary bladder cancers (Ohgaki et al, 1999). LOH on
both 11p and 11 q have frequently been reported in TCC of the
bladder (Fearon et al, 1985; Shaw and Knowles, 1995; Voorter et al,
1996; Monaco et al, 1997). Loss of 17p13.1, the TP53 locus, is asso-
ciated with high tumour grade (Tsutsumi et al, 1997; Esrig et al,
1993; Chaturvedi et al, 1997) and invasive growth in bladder cancer
(Tsutsumi et al, 1997). Loss of 17q22 and 17q24-25 have also been
reported (Chaturvedi et al, 1997). 
This study investigated LOH in 109 TCCs of the urinary
bladder from 46 patients with known follow-up. The patients fell
into two groups: those with carcinomas that did not recur and
those with carcinomas that recurred and/or progressed. LOH was
investigated using a panel of microsatellite markers that spanned
chromosomes 4, 8, 11 and 17. 
Loss of heterozygosity on chromosomes 11 and 17 
are markers of recurrence in TCC of the bladder 
J Edwards1, P Duncan1, JJ Going2, KM Grigor3, AD Watters1 and JMS Bartlett1
1University Department of Surgery and 2University Department of Pathology, Glasgow Royal Infirmary, Glasgow, G31 2ER; and 3University Department of
Pathology, Edinburgh Royal Infirmary, Edinburgh, EH8 9AG, UK 
Summary Approximately 2/3 of patients diagnosed with superficial transitional cell carcinoma of the urinary bladder (TCC) will recur within 2
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MATERIALS AND METHODS 
Patients and samples 
Forty-six patients were selected for this retrospective study. Ethical
approval was gained from the local ethics board. Patients either had
non-recurrent carcinomas (NR; n = 17) and were disease free with
follow-up for a minimum of 3 years or had recurrent carcinomas
(REC; n = 29). These patients had several episodes of recurrent
TCC after the index carcinoma. 
Archival (formalin fixed, paraffin embedded) TCCs were
regraded and staged by KMG using UICC criteria (UICC, 1978).
Tissue sections dewaxed in xylene (2 × 10 min), and rehydrated
through 99% alcohol (2 × 2 min) and 95% alcohol (2 min) were
stained in 0.05% Toludine blue for 30 s. Areas of tumour were
microdissected from 5 µ m sections. DNA was extracted by incu-
bating for 4–7 days at 37˚C in 25 µ l of proteinase K in digestion
buffer (0.5 mg/ml proteinase K, 0.5% Tween 20 in 50 mM Tris-
EDTA pH 8.5) (Going and Lamb, 1996). The proteinase K was inac-
tivated by heating at 95˚C for 10 min. Normal tissue (e.g. detrusor
muscle) was also dissected from the same section. LOH analysis was
conducted using 1 µ l aliquots of DNA without further purification. 
PCR 
Twenty-six microsatellites spanning four chromosomes were
investigated (Table 1). Primers were from MWG-Biotech UK Ltd
or Perkin-Elmer Applied Biosystems, with one primer from each
pair fluorescently labelled at the 5′ end all primer sequences are
available from the authors on request. 
Target sequences were amplified by PCR in 10 µ l reactions (1×
reaction buffer containing 10 pmol of each primer, 3 mM MgCl2,
200 µ M each of dATP, dCTP, dGTP, dTTP and 0.5 units hot start
Taq polymerase (Qiagen Ltd, Sussex, UK)). The reaction was
started after 15 min denaturation of DNA at 95˚C. DNA amplifi-
cation was performed in a MJ Research PTC – 225 Peltier
Thermal Cycler (Genetic Research Instrumentation, Essex, UK) as
follows: 45 cycles of denaturation at 94˚C for 30 s, annealing at
47, 49, 50, 51 or 53˚C (Table 1) for 30 s and extension at 72˚C for
1 min, followed by a final extension for 15 min at 72˚C. 
PCR analysis 
Genotyping was performed on an automated laser activated fluo-
rescent DNA sequencer (Perkin Elmer ABI 377 sequencer) by
DNASHEF Technologies, Edinburgh. Fluorescent gel data were
collected automatically during electrophoresis and analysed using
Genescan™ software, peak size, height and area were measured.
Allele loss was assessed as described by Niederacher et al, (1997),
i.e. the allele ratio of carcinoma DNA peak height was divided by
the allele ratio of paired normal DNA peak height. A ratio below
0.65 or above 1.55 was considered indicative of loss. Repeat
analysis was performed on random samples to confirm repro-
ducibility. 
Statistics 
Differences between patient groups were analysed using Fisher’s
exact test. Disease free survival was evaluated using the Kaplan-
Meier method and curves were compared with the log rank test. 
RESULTS 
There were no significant differences between patient age or sex or
index carcinoma stage or grade when the NR and REC groups
were compared. The stage and grade of all carcinomas used were
known (Table 2). The success rate of LOH analysis from archival
carcinoma material was greater than 95%. 
Index carcinomas 
The frequency of LOH at all informative markers spanning chromo-
somes 4, 8, 11 and 17 were compared in index NR and index REC
Table 1 Outlines the microsatellites studied, their chromosomal region and
the annealing temperature of their PCRs 
Microsatellite markers Region Temperature (˚C) 
D4S174 4p11–15 50 
D4S127 4p16.3 53 
D8S254 8p22 50 
D8S133 8p22 50 
D10S215 10q23.1 47 
D11S922 11p15.5 53 
D11S569 11p15.1 50 
FGF3 11q13 53 
D11S490 11q23.3 50 
D17S578 17p13.3 49 
D17S849 17p13.3 50 
D17S960 17p13.1 49 
TP53 17p13.1 50 
D17S786 17p13.1 49 
D17S1852 17p13.1 50 
D17S799 17p12 50 
D17S921 17p12 50 
D17S1857 17p12 50 
D17S798 17q11–12 50 
D17S932 17q21 49 
D17S579 17q21 51 
D17S943 17q21 49 
D17S944 17q21 51 
D17S807 17q21 49 
D17S949 17q21 50 
D17S784 17q24–25 51 
D17S928 17q24–25 51 
Table 2 Shows the stage and grade of carcinomas, NR denotes non recurrers, index (REC) denotes the
index carcinomas of patients with subsequent recurrences and recurrent (REC) denotes the recurrent
carcinomas 
Stage Grade 
Ta T1 T2 Other 1 2 3 
NR 13/17 4/17 6/17 11/17 
Index (REC) 17/29 9/29 3/29 11/29 10/29 5/29 
Recurrent (REC) 37/63 11/63 15/63 21/63 18/63 24/63 1896 J Edwards et al
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carcinomas; no significant differences were identified (Table 3). No
significant differences were identified when loss of chromosomal
regions were compared for index NR and index REC carcinomas. 
The frequency of loss of D11S490 was significantly higher in
patients who recurred compared to patients who did not recur (NR,
25%, 3/12 versus REC, 81%, 13/16, P = 0.004) (Figure 1). This
held true when pTa carcinomas alone were considered (NR, 20%
2/10, versus REC 89%, 8/9, P = 0.001). Time to recurrence was
significantly longer in patients who retained D11S490 than in
those who lost it (Figure 2, P = 0.0079); 16 patients out of 28
informative cases had LOH at D11S490. 
The frequency of loss of D17S928 was significantly higher in
the index carcinomas from the REC group compared to NR car-
cinomas (NR, 21%, 3/14 versus REC, 80%, 16/20, P = 0.002)
(Figure 1). This held true when the pTa carcinomas alone were
considered (NR, 15%, 2/13 versus REC, 83%, 10/12, P = 0.002).
Time to recurrence was significantly longer in patients who
retained D17S928 than in those who lost it (Figure 3, P = 0.04);
19 patients out of 34 informative cases had LOH at D17S928. 
LOH data from D11S490 and D17S928 identified 23 out of the
29 patients as likely to recur compared to 13 for D11S490 and 16
for D17S928. All patients were included and none were lost due to
non informative markers. Time to recurrence was significantly
shorter in patients who had LOH at either D11S490 and D17S 928
than in those who had retention at either or both (P = 0.03). 
Table 3 Shows the frequency of LOH at all informative markers spanning
chromosome 4.8, 11 and 17 in two patient groups. NR = non-recurrers and
REC = recurrers 
NR REC 
Chromosome 4 29% (5/17) 21% (6/28) 
Chromosome 8 12% (2/17) 3% (1/28) 
Chromosome 11 0% (0/17) 18% (5/28) 
Chromosome 17 0% (0/17) 0% (0/28) 
Figure 1 LOH frequency at each loci for the index carcinomas of the NR and REC groups 
Figure 2 Disease free survival of 28 patients who retained or had LOH at
D11S490 (P = 0.0079) 
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The trend in total LOH frequency as a carcinoma recurs
and progresses 
The trend of LOH in recurrent carcinomas was investigated, the
REC group being sub-divided into carcinomas that recurred (RNP)
and carcinomas that recurred and progressed to higher stage
disease (RP). The frequency of LOH in each group was calculated
by dividing the total number of informative cases by the total
number of LOHs in each group and multiplying by 100, therefore
the frequency was expressed as a percentage. In the RNP group
there was no significant difference in the frequency of LOH
observed in index and recurrent carcinomas (index tumour 40%
(116/316), first recurrence 47% (146/310) and last recurrence 48%
(117/241). In the RP patient group the frequency of LOH
increased with progression: 32% (66/205) of index carcinomas,
47% (88/ 187) of first recurrent carcinomas, 51% (99/192) of
immediately pre-invasive carcinomas and 61% (90/148) of post-
invasive carcinomas. As the index carcinoma progressed to an
invasive carcinoma a significant increase in the frequency of LOH
was noted (P > 0.0001) (Figure 4). 
The significance of LOH levels in carcinomas grouped
by grade and stage 
When carcinomas were grouped by stage and the frequency of
LOH compared for individual loci or chromosomal regions the
only significant difference was at 8p22, pTa carcinomas had
a significantly lower frequency of LOH than pT1 carcinomas
(19/39, 48% versus 10/11, 91% P = 0.024). 
When the frequency of LOH was compared for carcinomas
grouped by grade, loss of all informative markers spanning the
TOP II region on chromosome 17 was found to increase with
grade. (Grade 1, 2/33, 6% versus grade 2, 9/25, 36%, P = 0.01; and
grade 1, 2/33, 6% versus grade 2 and 3, 15/49, 25%, P = 0.01). 
DISCUSSION 
Current molecular and pathological parameters fail to predict
which early TCCs will recur and/or progress. This study assessed
genetic changes on chromosome 4, 8, 11 and 17 in two patient
groups in an attempt to identify genetic changes in index carci-
nomas that would predict the path a carcinoma might follow. The
index carcinomas investigated were either pTa or pT1. The results
were analysed with pTa and pT1 index carcinomas combined and
separated as genetic differences between pTa and pT1 carcinomas
have now been identified (Richter et al, 1997; Simon et al, 1998).
Interestingly only one marker had significantly different frequency
of LOH when the carcinomas were grouped by stage (8p22 between
pTa and pT1) or grade (17p21 between grade 1 and grade 2). These
results suggest that the frequency of LOH at the microsatellite loci
used in this study is independent of stage or grade. 
Frequent deletions on both arms of chromosome 11 in TCC of
the urinary bladder indicate the probable location of relevant
tumour suppressor gene/s (Fearon et al, 1985; Voorter et al, 1996).
Distinct regions of deletion exist on 11p (11p13 and 11p15) and
11q (11q13–q23.3), and LOH in these regions is associated with
high grade carcinomas (Shaw and Knowles, 1995). Chromosome
11 analysis in this study focused on these regions. The frequency
of LOH was compared at 11p13, 11p15, 11q13 and 11q23 in index
carcinomas from NR and REC patients. There was more frequent
LOH at D11S490 (11q23) in index REC carcinomas than NR
carcinomas (P = 0.004). Chromosomal deletions at region 11q23,
have been associated with human carcinomas including lung
(Iizuka et al, 1995), ovarian (Foulkes et al, 1993) and uterine
cervix (Hampton et al, 1994), suggesting the presence of at least
one tumour suppressor gene in this area. Several candidate genes
linked to carcinogenesis at 11q23 include Cbl,  EST1,  DDX6,
tumour suppressor gene on chromosome 11 (TSG11) (locus link)
and LOH11CRA (Monaco et al, 1997). The two most likely candi-
date genes are Cbl and TSG11. Cbl protein is a central player in the
regulation of tyrosine kinase signalling pathways and is therefore
implicated in many growth and apoptotic pathways (Lupher et al,
1998). TSG11 has been demonstrated as a tumour suppressor gene
in lung cancer and possibly a variety of other cancers (Murakami
et al, 1998). Although LOH11CRA is hypothesized as a possible
carcinoma suppressor gene its function is unknown. Further inves-
tigations are required but it appears that deletion of 11q23 repre-
sents an important genetic event in the recurrence of bladder
cancer. 
In TCC of the bladder LOH studies on chromosome 17 have
tended to focus on 17p13 where TP53 lies, there is therefore 
relatively little information available on loss of 17q. Losses at
17q11–22 and 17q24–25 have, however, been reported (Chaturvedi
et al, 1997). The current study therefore investigated LOH on chro-
mosome 17 using 18 microsatellites that span the chromosome, 8 of
these markers are on 17q. The frequency of LOH at individual
markers spanning chromosome 17 ranged from 7% to 80%
Figure 4 Overall percentage of LOH noted in index, first recurrence,
immediately pre-invasive and muscle invasive carcinomas of patients who
presented with a low grade carcinoma which recurred and progressed to a
muscle invasive carcinoma (RP) 
Figure 3 Disease free survival of 34 patients who retained or had LOH at
D17S928 (P = 0.04) 
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depending on the locus investigated. D17S928 (17q25) had the
highest frequency of LOH, and was associated with recurrence. Loss
of 17q25 is found in breast and ovarian carcinomas (Kalikin et al,
1996, 1997) and is independent of BRCA 1 deletions. LOH and
functional suppression studies in breast, ovarian and oesophageal
cancer, support the existence of a novel tumour suppressor gene at
17q24–25 (Jacobs et al, 1993; Godwin et al, 1994; Theile et al,
1995; Plummer et al, 1996; Petty et al, 1998). Candidate genes at
17q24–25 include Thymidine kinase 1 (TK1) and apoptosis
inhibitor 4 (API4). TK1 encodes soluble thymidine kinase (TK1)
which catalyses the phosphorylation of thymidine to deoxythymi-
dine monophosphate and is associated with cell division (Petty et al,
1998). LOH at 17q24–25 is postulated to increase TK1 activity in
breast cancer (Petty et al, 1996), and TK1 levels in breast tumours
and serum predict recurrence (O’Neill et al, 1992). AP14 encodes
for survivin, which has abundant expression in lung, pancreas,
breast and prostate cancer (Ambrosini et al, 1997). Survivin is
expressed in G2/M and associates with microtubules of the mitotic
spindle at the beginning of mitosis (Li et al, 1998). It is believed to
counteract induction of apoptosis in G2/M (Li et al, 1998).
Therefore, LOH at this region might interfere with the cell cycle and
promote recurrence of TCC of the urinary bladder. Further mapping
studies of this area of chromosome 17 and functional studies are
required to confirm a role for these candidate genes. 
The total frequency of LOH increased with recurrence and
progression, demonstrating an accumulation of genetic defects
throughout the disease history, but whether this is a cause or a
consequence of TCC progression is unknown. Increased LOH
with progression was most noticeable at TP53, D17S807,
D11S922 and D11S569 (data not shown). Increased LOH at TP53
with carcinoma progression is not surprising as TP53 alterations
are frequently associated with muscle invasivion (Spruck et al,
1994; Sidransky et al, 1991; Chaturvedi et al, 1997). 
Genetic differences exist between low grade TCC which may
determine subsequent tumour behaviour and identification of the
associated tumour suppressor genes is required for better under-
standing of bladder carcinogenesis. 
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